Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg),… was recalled on August 6, 2026 in cooperation with the U.S. Food and Drug Administration because subpotent Drug.
Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), packaged in a) 90-count bottles (NDC 16729-456-15), and b) 1000-count bottles (NDC 16729-456-17), Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India.
a) Lot #: D2402642, Exp. Date 11/30/2026 b) Lot #: D2401832, Exp. Date 08/31/2026; D2402525, D2402527, D2402526, D2402644, D2402643, Exp. Date 11/30/2026.
Units affected: N/A
Where it was sold: Nationwide within the United States
Compare the codes above against the label on your product — usually on the bottom, the back panel, or the packaging. If your unit isn't listed, it is not part of this recall.
Subpotent Drug
Class II means the product might cause a temporary or medically reversible health problem; the chance of serious harm is remote.
Stop using the product. Return it to the place of purchase for a refund, or dispose of it. Contact the recalling firm with questions.
Contact: Recalling firm: ACCORD HEALTHCARE, INC.
Not sure what you're entitled to? Read our guide: what to do if your product is recalled.
Always confirm details on the official notice from the U.S. Food and Drug Administration before acting.
View official notice →The recalled bicycles' front lock nut can loosen during use, causing the front wheel to dislodge or loosen over time, posing a crash hazard.
When plugged in or switched on, the lamp cord or internal wiring can smoke, melt, spark, overheat or ignite, posing a risk of serious injury from fire and burn hazards.
Failed Content Uniformity Specifications
Failed Impurities/Degradation Specifications
Be the first to know when products like this are recalled. Free weekly digest, unsubscribe anytime.